Hunt joins the company from HeartBeam.
Jon Hunt, PhD, is joining Impicity as chief commercial officer.
Previously, Hunt worked for HeartBeam, a cardiac technology company, as an executive vice president and chief business officer. He has worked in the cardiovascular device industry for nearly 40 years.
In a press release, CEO and co-founder of Implicity Dr. Arnaud Rosier, said, “Having an executive of Jon's caliber and experience is key to achieving our goal of becoming the leader in remote cardiac monitoring in the U.S. market. Jon brings extensive experience in the CRM/EP market and a proven track record of scaling startup companies and building commercial teams. We look forward to his guidance and expertise as we continue to build on our successes and provide healthcare professionals nationwide with more effective solutions for managing heart disease.”.
Implicity is a digital medtech software company that produces a platform that collects and standardizes data from a variety of implantable cardiac devices from different companies.
(Sept. 27, 2023); Implicity; Implicity Expands Senior Leadership Team with New US Chief Commercial Officer; https://www.prnewswire.com/news-releases/implicity-expands-senior-leadership-team-with-new-us-chief-commercial-officer-301939282.html
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.